Verteporfin

• CAT Number: I013885
• CAS Number: 129497-78-5
• Molecular Formula: C₄₁H₄₂N₄O₈
• Molecular Weight: 718.79
• Purity: ≥95%
• Target: YAPAutophagy
• Solubility: DMSO: 5.6 mg/mL
• IUPAC Name: 3-[(23R,24S)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
• InChI: InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1
• InChIKey: NJLRKAMQPVVOIU-IDLGWYNRSA-N
• SMILES: CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C

Verteporfin(CAT: I013885) is a medication used in photodynamic therapy (PDT) for the treatment of certain eye conditions. It is a photosensitizing agent that is activated by light to produce reactive oxygen species, leading to localized tissue damage. In ophthalmology, verteporfin is primarily employed in the treatment of age-related macular degeneration (AMD), specifically the predominantly classic subtype. It is administered intravenously and selectively accumulates in abnormal blood vessels in the eye. Upon activation by laser light, it causes occlusion and destruction of these vessels, helping to slow down the progression of AMD and preserve vision.

Reference

1. Morishita T, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. Oncotarget. 2016 Aug 2.
2. Pan W, et al. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression. Cell Physiol Biochem. 2016;39(2):481-90.
3.Schmidt-Erfurth, Ursula, and Tayyaba Hasan. "Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration." Survey of ophthalmology 45.3 (2000): 195-214.
4.Donohue, Elizabeth, et al. "Induction of covalently crosslinked p62 oligomers with reduced binding to polyubiquitinated proteins by the autophagy inhibitor verteporfin." PloS one 9.12 (2014): e114964.